ProQR Therapeutics Investor Relations Material
Latest events
Status Update
ProQR Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from ProQR Therapeutics N.V.
Access all reports
ProQR Therapeutics N.V. is a biotechnology company focused on developing innovative RNA therapies for genetic diseases. Established in 2012 in Leiden, Netherlands, ProQR pioneers RNA editing technologies, specifically its proprietary platform called Axiomer. This technology enables precise RNA editing by using a cell's own ADAR enzymes to alter specific nucleotides in RNA molecules, potentially reversing mutations or modulating protein expression to address unmet medical needs in various diseases. The company's approach to drug development is particularly significant for conditions that currently lack effective treatments. Over the years, ProQR has expanded its pipeline beyond its initial focus on cystic fibrosis to include a range of rare and common diseases, with ongoing research and development efforts in fields such as inherited retinal diseases and liver diseases. The company is headquartered in Leiden, Netherlands, and its shares are listed on the NASDAQ.
Latest articles
Amazon's Most Notable Acquisitions Since Inception
Explore Amazon's most impactful acquisitions, from IMDb and Zappos to Whole Foods and MGM, and how these have diversified its business.
13 May 2024
Adidas vs Puma: The Story of the Dassler Brothers
An in-depth article outlining the story of the Dassler brothers, their feud with one another, and the history of Puma and Adidas.
10 May 2024
Satya Nadella: The Architect of Microsoft's Resurgence
The journey of Satya Nadella, from his early life in India to reshaping Microsoft as its CEO, emphasizing cloud computing and inclusive leadership.
10 May 2024
Ticker symbol
Country
đșđž United States